Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Bozhena Vynnytska-Myronovska"'
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 6, p 5648 (2023)
The tyrosine kinase inhibitor (TKI) cabozantinib might impede the growth of the sunitinib-resistant cell lines by targeting MET and AXL overexpression in metastatic renal cell carcinoma (mRCC). We studied the role of MET and AXL in the response to ca
Externí odkaz:
https://doaj.org/article/9373c472842945bcb74a234d3276bce7
Publikováno v:
Cancer Research. 82:5502-5502
The VEGFR/MET/AXL receptor tyrosine kinase inhibitor, Cabozantinib (Cbz), showed clinical benefits in first- and second-line treatment for selective metastatic renal cell carcinoma (mRCC) patients. We tested the molecular effects of Cbz in treatment-
Autor:
Melanie Hüther, Oleh V. Stasyk, Claudia Dittfeld, Yuliya Kurlishchuk, Bozhena Vynnytska-Myronovska, Leoni A. Kunz-Schughart, Oleh Chen, Yaroslav Bobak
Publikováno v:
Experimental Cell Research. 341:67-74
Tumor cells rely on a continued exogenous nutrient supply in order to maintain a high proliferative activity. Although a strong dependence of some tumor types on exogenous arginine sources has been reported, the mechanisms of arginine sensing by tumo
Autor:
Maria Jolanta Redowicz, Oleh V. Stasyk, Yuliya Kurlishchuk, Galyna Shuvayeva, Leoni A. Kunz-Schughart, Yaroslav Bobak, Olesia Grydzuk, Bozhena Vynnytska-Myronovska
Publikováno v:
The International Journal of Biochemistry & Cell Biology. 70:29-38
Deprivation for the single amino acid arginine is a rapidly developing metabolic anticancer therapy, which allows growth control in a number of highly malignant tumors. Here we report that one of the responses of human solid cancer cells to arginine
Publikováno v:
Cancer Research. 80:5272-5272
Introduction: The tyrosine kinase inhibitors Sunitinib and Pazopanib have been established in firstline treatment of metastatic renal cell carcinoma (mRCC) patients especially in the good prognosis group. Despite the primary response many patients be
Autor:
Bozhena Vynnytska-Myronovska, Yaroslav Bobak, Yuliya Kurlishchuk, Oleh V. Stasyk, Claudia Dittfeld, Leoni A. Kunz-Schughart
Publikováno v:
Amino Acids. 45:1221-1230
Increased amino acid requirement of malignant cells is exploited in metabolic antitumor therapy, e.g., enzymotherapies based on arginine or methionine deprivation. However, studies on animal models and clinical trials revealed that solid tumors are m
Autor:
Leoni A. Kunz-Schughart, Oleg Chen, F. Manig, Sebastian R. Merker, Daniel E. Stange, Oleh V. Stasyk, Yaroslav Bobak, Philipp Grosse-Gehling, Thomas Henle, Yuliya Kurlishchuk, Steffen Löck, Bozhena Vynnytska-Myronovska
Publikováno v:
Oncotarget
// Yuliya Kurlishchuk 1, 2 , Bozhena Vynnytska-Myronovska 1, 2, 6 , Philipp Grosse-Gehling 1 , Yaroslav Bobak 2 , Friederike Manig 1, 3 , Oleg Chen 1, 2 , Sebastian R. Merker 4 , Thomas Henle 3 , Steffen Lock 1 , Daniel E. Stange 4 , Oleh Stasyk 2 ,
Autor:
Kerstin Junker, Michael Stoeckle, Bozhena Vynnytska-Myronovska, J. Heinzelmann, Sebastian Hölters
Publikováno v:
Cancer Research. 78:2840-2840
BACKGROUND: Together with Sunitinib (Sun), Pazopanib (Paz) is considered as a gold standard in metastatic renal cell carcinoma treatment (RCC). Similarly to other tyrosine kinase inhibitors (TKI), development of resistance constitutes the main proble
Autor:
Olga Basaraba, Thomas Kietzmann, Kseniya Palyvoda, Halyna Shuvayeva, Oksana Mayevska, Yuriy Rzhepetsky, Anatoliy Samoylenko, Bozhena Vynnytska-Myronovska, Nataliya Volodko, Nadiya Byts, Nina Kozlova, Yaroslav Bobak, Volodymyr Savran, Vladimir L. Buchman, Lyudmyla Drobot, Ganna Pasichnyk, Maryna Barska, Valeriy V. Lyzogubov, Vasyl Usenko
Publikováno v:
Carcinogenesis. 33(10)
The adaptor protein regulator for ubiquitous kinase/c-Cbl-interacting protein of 85kDa (Ruk/CIN85) was found to modulate HER1/EGFR signaling and processes like cell adhesion and apoptosis. Although these features imply a role in carcinogenesis, it is
Autor:
Leoni A. Kunz-Schughart, Yvette Garbe, Yaroslav Bobak, Bozhena Vynnytska-Myronovska, Claudia Dittfeld, Oleh V. Stasyk
Publikováno v:
International journal of cancer. 130(9)
Single amino acid arginine deprivation is a promising strategy in modern metabolic anticancer therapy. Its potency to inhibit tumor growth warrants the search for rational chemo- and radio-therapeutic approaches to be co-applied. In this report, we e